Myelofibrosis or Essential Thrombocythemia (INCB-MA-MF-401) Registry

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• MF cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR intermediate-1 risk by DIPSS by reason of age alone.
• ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR currently receiving ET-directed therapy (eg, hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib, etc).
• Willing and able to provide written informed consent.
• Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel.
• Under the supervision of a physician for the current care of MF or ET.

A patient will not be eligible for participation in this study if any of the following criteria apply.

• Individuals who are participating in blinded investigational drug studies.
• Individuals who are participating in Incyte investigational/interventional drug trials (company- or investigator-sponsored studies) until they have completed the 30-day end of study visit.
• Life expectancy ≤ 6 months.
• Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, or secondary thrombocytosis.

To learn more, visit ClinicalTrials.Gov

Study Type

Phase: N/A

Principal Investigator(s)

Asim Pati, MD

Sponsor(s)

Incyte Corporation